A resveratrol relative absorbed far more efficiently, pterostilbene appears to switch on cellular repair and antioxidant systems similar to eating less. Human evidence is limited: a modest blood-pressure drop, but a rise in bad cholesterol worth watching. Longevity and anticancer promise rests on animal work. Short-term use appears safe and well tolerated. (Full Review)

Protocol

Standard Dose

50–250 mg/day

250 mg/day often split as 125 mg twice daily; 50 mg common in NAD+ combination products

Timing

With a fatty meal

Taken with fat to aid absorption; morning dosing common

Dosing Schedule

Twice daily

Split dosing given the short 1–2 hour half-life

Time to effect

Blood Pressure

6–8 weeks

Systolic and diastolic reductions in the human trial

Evaluation Window

2–3 months

Reasonable trial length with before-and-after labs

Liver Enzymes

~6 months

ALT and GGT reductions with the nicotinamide-riboside combination

Benefits

Medium: Blood pressure reduction; reduced oxidative stress and inflammation

Low: Metabolic and liver support; cognitive and neuroprotective effects; NAD+ and cellular-energy support

Speculative: Lifespan and healthspan extension; anticancer and chemopreventive potential

Contraindications

Pregnancy or breastfeeding

Hormone-sensitive conditions

Existing high LDL cholesterol

Surgery within 1–2 weeks

Multiple medications cleared by conjugation enzymes

Key Interactions

Antihypertensives (amlodipine, lisinopril, losartan)

Anticoagulants and antiplatelet drugs (warfarin, clopidogrel)

NSAIDs (ibuprofen, naproxen)

Acetaminophen

Blood-pressure-lowering supplements (magnesium, potassium, garlic extract, CoQ10)

Resveratrol

Risk & Side Effects

Medium: LDL cholesterol elevation

Low: Gastrointestinal discomfort; additive blood-pressure lowering

Speculative: Drug-metabolism interactions; theoretical hormonal activity

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mmHg	Tracks the main documented benefit; guards against excessive lowering
LDL cholesterol	<100 mg/dL	Detects the key documented risk
Total cholesterol & lipid panel	Total <180–200 mg/dL; HDL >50 mg/dL	Contextualizes any LDL change and overall lipid balance
ALT & GGT	ALT <25 U/L; GGT <25 U/L	Monitors liver safety and the combination-product benefit signal
Fasting glucose & HbA1c	Glucose 75–90 mg/dL; HbA1c <5.4%	Screens the metabolic effects seen in animal and combination studies
hs-CRP	<1.0 mg/L	Captures the anti-inflammatory effect on a general inflammation marker
eGFR & creatinine	eGFR >90 mL/min/1.73m²	Baseline safety context, relevant to combination-product kidney research

Cadence: Baseline before starting, first recheck at 8–12 weeks (lipid panel and blood pressure), then every 6–12 months if continued long-term

Qualitative Assessment

Energy levels and daytime alertness
Exercise tolerance and recovery
Cognitive clarity and focus
General sense of well-being and absence of digestive upset

Pterostilbene for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment